We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-5.44%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.92B
AUM Growth
-$82.3M
Cap. Flow
-$215M
Cap. Flow %
-11.22%
Top 10 Hldgs %
52.67%
Holding
387
New
94
Increased
95
Reduced
80
Closed
99

Sector Composition

Rank Sector Weight
1 Healthcare 12.85%
2 Industrials 0.12%
3 Consumer Staples 0.07%
4 Consumer Discretionary 0.06%
5 Technology 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LUMO
226
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$318K 0.02%
3,140
-11,022
-78% -$1.37M
ANTH
227
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$309K 0.02%
12,500
-12,365
-50% -$349K
CYNA
228
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$305K 0.02%
18,194
-48,328
-73% -$650K
AGPU
229
Axe Compute Inc
AGPU
$83.5M
$298K 0.02%
26
-1
-4% -$13.3K
ACRS icon
230
Aclaris Therapeutics
ACRS
$744M
$292K 0.02%
+15,812
New +$313K
NURO
231
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$286K 0.01%
269
+137
+104% +$156K
MDVN
232
DELISTED
MEDIVATION, INC.
MDVN
$271K 0.01%
+4,500
New +$255K
MDVN
233
PUT
DELISTED
MEDIVATION, INC.
MDVN
$271K 0.01%
+45
New +$2.55K
OCGN icon
234
Ocugen
OCGN
$420M
$258K 0.01%
2,511
ACOR
235
PUT
DELISTED
Acorda Therapeutics
ACOR
$255K 0.01%
+1
New +$3.25K
AMRN
236
PUT
Amarin Corp
AMRN
$293M
$241K 0.01%
56
AKTX
237
Akari Therapeutics
AKTX
$14.8M
$235K 0.01%
22
-29
-57% -$374K
MDCO
238
DELISTED
Medicines Co
MDCO
$235K 0.01%
+7,000
New +$247K
ABUS icon
239
CALL
Arbutus Biopharma
ABUS
$871M
$233K 0.01%
669
+39
+6% +$165
THC icon
240
CALL
Tenet Healthcare
THC
$22.6B
$224K 0.01%
+81
New +$2.39K
CLRBW
241
DELISTED
Cellectar Biosciences, Inc.
CLRBW
$219K 0.01%
230,013
+164,651
+252% +$100K
STAF
242
DELISTED
Staffing 360 Solutions, Inc. Common Stock (DE)
STAF
$216K 0.01%
+46
New +$333K
RLYP
243
CALL
DELISTED
RELYPSA INC COM
RLYP
$213K 0.01%
115
-358
-76% -$6.29K
CDTX
244
DELISTED
Cidara Therapeutics
CDTX
$209K 0.01%
1,014
-1,000
-50% -$242K
ONSIW
245
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$209K 0.01%
+426,184
New +$163K
ATHX
246
DELISTED
Athersys, Inc. Common Stock
ATHX
$199K 0.01%
+3,670
New +$208K
ONSIZ
247
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$196K 0.01%
+436,923
New +$230K
LPCN icon
248
Lipocine
LPCN
$17.6M
$194K 0.01%
3,757
-5,130
-58% -$795K
ARCT icon
249
PUT
Arcturus Therapeutics
ARCT
$163M
$184K 0.01%
+58
New +$1.83K
NTRA icon
250
CALL
Natera
NTRA
$36.1B
$174K 0.01%
+144
New +$1.6K

Similar funds

Sabby Management's Q2 2016 Portfolio in Review

As of Q2 2016, Sabby Management held 387 positions worth $1.92B, down 4.1% from $2B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $215M in Q2 2016, closing 99 positions and reducing 80 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 12% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Abbott worth $10.4M.

  • Sabby Management's largest Q2 2016 buy was Abbott: 264,700 shares worth $10.4M.
  • Sabby Management added most to Regeneron Pharmaceuticals in Q2 2016, an estimated $12.5M increase.
  • Sabby Management's biggest Q2 2016 reduction was Biogen, cutting an estimated $7.14M.
  • Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2016, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.92B portfolio in Q2 2016.
  • Sabby Management opened 94 new positions and closed 99 in Q2 2016.
  • Sabby Management's portfolio value fell 4.1% quarter-over-quarter to $1.92B.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.